These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26111575)

  • 1. Intravitreal Ranibizumab in Daily Clinical Practice for Age-Related Macular Degeneration: Treatment of Exudative Age-Related Macular Degeneration in Real Life.
    Cazet-Supervielle A; Gozlan J; Cabasson S; Boissonnot M; Manic H; Leveziel N
    Ophthalmologica; 2015; 234(1):26-32. PubMed ID: 26111575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
    Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT
    BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ranibizumab and exudative age-related macular degeneration: 5-year multicentric functional and anatomical results in real-life practice].
    Boulanger-Scemama E; Sayag D; Ha Chau Tran T; Quaranta-El Maftouhi M; Rumen F; Creuzot-Garcher C; Blanco Garavito R; Jung C; Souied E
    J Fr Ophtalmol; 2016 Oct; 39(8):668-674. PubMed ID: 27609025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register.
    Westborg I; Granstam E; Rosso A; Albrecht S; Karlsson N; Lövestam-Adrian M
    Acta Ophthalmol; 2017 Dec; 95(8):787-795. PubMed ID: 28834299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of exudative age-related macular degeneration with intravitreal ranibizumab in clinical practice: a 3-year follow-up.
    Marques IP; Fonseca P; Luz Cachulo M; Pires I; Figueira J; Faria de Abreu JR; Silva R
    Ophthalmologica; 2013; 229(3):158-67. PubMed ID: 23485818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Choroidal Topographic Changes by Swept-Source Optical Coherence Tomography After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
    Razavi S; Souied EH; Darvizeh F; Querques G
    Am J Ophthalmol; 2015 Nov; 160(5):1006-13. PubMed ID: 26275471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration.
    Lala C; Framme C; Wolf-Schnurrbusch UE; Wolf S
    Acta Ophthalmol; 2013 Sep; 91(6):526-30. PubMed ID: 22697404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
    Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
    Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration.
    Kang HM; Lee SJ; Kim CG; Chung EJ; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1681-92. PubMed ID: 26743753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EFFECT OF INTRAVITREAL RANIBIZUMAB ON GANGLION CELL COMPLEX AND PERIPAPILLARY RETINAL NERVE FIBER LAYER IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY.
    Zucchiatti I; Cicinelli MV; Parodi MB; Pierro L; Gagliardi M; Accardo A; Bandello F
    Retina; 2017 Jul; 37(7):1314-1319. PubMed ID: 28574419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration.
    Valverde-Megías A; Ruiz-Calvo A; Murciano-Cespedosa A; Hernández-Ruiz S; Martínez-de-la-Casa JM; García-Feijoo J
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1459-1466. PubMed ID: 31053943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration.
    Parodi MB; Iacono P; La Spina C; Iuliano L; Lo Giudice G; Introini U; Bandello F
    Retina; 2014 Nov; 34(11):2167-70. PubMed ID: 24999724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS; Daftari I; Phillips T; Morse LS
    Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Nguyen CL; Gillies MC; Nguyen V; Daien V; Cohn A; Banerjee G; Arnold J;
    Ophthalmology; 2019 May; 126(5):735-742. PubMed ID: 30529685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
    Jackson TL; Chakravarthy U; Kaiser PK; Slakter JS; Jan E; Bandello F; O'Shaughnessy D; Gertner ME; Danielson L; Moshfeghi DM;
    Ophthalmology; 2013 Sep; 120(9):1893-900. PubMed ID: 23490327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.